Non‐rhabdomyosarcoma soft‐tissue sarcoma. (5th April 2021)

• Record Type: Journal Article
• Authors: Milgrom, Sarah A.; Million, Lynn; Mandeville, Henry; Safwat, Akmal; Ermoian, Ralph P.; Terezakis, Stephanie
• Is Part Of: Pediatric blood & cancer. Volume 68(2021)Supplement 2
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-04-05
• Subjects: chemotherapy -- COG -- non‐rhabdomyosarcoma soft‐tissue sarcoma -- NRSTS -- pazopanib -- radiation therapy -- sarcoma -- SIOP -- surgery; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.28279
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Non‐rhabdomyosarcoma soft‐tissue sarcomas (NRSTS) comprise 4% of childhood cancers and consist of numerous histologic subtypes. Prognostic factors associated with poor outcome include high histologic grade, large tumor size, presence of metastases, and unresectability. Complete surgical resection is critical for the best oncologic outcomes and is prioritized in treatment algorithms. The use of radiation therapy (RT) and chemotherapy is based upon factors such as resectability, histologic grade, tumor size, and stage. North American and European trials are defining a risk‐based approach to NRSTS to limit treatment‐related toxicity and to maximize therapeutic efficacy. In this paper, we summarize the current roles of surgery, RT, and chemotherapy in NRSTS and describe ongoing research that is advancing the care of NRSTS patients.